Merck
FDA approves Liptruzet
May 7, 2013Sales and Marketing FDA, Merck, liptruzet
Merck is celebrating after its once-daily anti-cholesterol pill Liptruzet was approved by US regulators, expanding its indications. The drug – …
Pfizer and Merck create major diabetes alliance
April 30, 2013Research and Development, Sales and Marketing Merck, Pfizer, diabetes
Pfizer and Merck have unveiled a major new alliance in diabetes which is likely to raise the stakes in the …
Melanoma breakthrough for Merck
April 26, 2013Research and Development, Sales and Marketing FDA, Merck, lambrolizumab, melanoma
Merck’s pipeline has been given a boost by an FDA decision to designate early-stage investigational drug lambrolizumab as a breakthrough …
HCV agreement for Merck and BMS
April 23, 2013Research and Development, Sales and Marketing BMS, HCV, Merck
Merck & Co and Bristol-Myers Squibb have signed a non-exclusive agreement to conduct a Phase II trial looking at a …
Merck opens $120m China factory
April 19, 2013Manufacturing and Production, Sales and Marketing China, Merck
Merck is to open a new manufacturing facility in Hangzhou, two decades after the company built its first plant in …
Big pharma appointments to PhRMA Board
April 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Big Pharma, Celgene, Merck, Pfizer, PhRMA
Chairman and chief executive of Celgene Robert Hugin has been elected chairman of the Pharmaceutical Research and Manufacturers of America …
Merck makes Alzheimer’s deal
March 14, 2013Research and Development, Sales and Marketing Alzheimer's, Merck
Merck is teaming up with Texas-based Luminex Corporation to develop a companion diagnostic to help in its dementia programme. The …
Merck to close Irish manufacturing unit
March 11, 2013Manufacturing and Production MSD, Merck
Merck & Co has said that a manufacturing unit in Rathdrum, Ireland will close by the end of 2015 with …
Merck suffers brain cancer reverse
February 26, 2013Sales and Marketing Merck, cilengitide
Merck’s oncology programme has suffered a setback as a Phase III trial of its investigational integrin inhibitor cilengitide failed in …
Merck makes $688m payout
February 18, 2013Sales and Marketing ENHANCE, Inegy, Merck, Vytorin, investors
Merck has paid out $688 million to end two class-action lawsuits which sprang up after the revelation of disappointing trial …
Merck planning more manufacturing cutbacks?
February 11, 2013Manufacturing and Production Merck, restructuring
Merck & Co has said it intends to make additional reductions to its manufacturing network, although the pace of restructuring …
Facility of the year: 2013 winners announced
February 4, 2013Manufacturing and Production Biogen, MedImmune, Merck, Novartis, Roche
Three US and three European manufacturing plants have been selected as category winners for the annual Facility of the Year …
Amgen earmarks $200m for new Singapore plant
January 18, 2013Manufacturing and Production Amgen, Merck, Singapore
Amgen has unveiled plans to construct a new manufacturing plant in Singapore, its first production facility in Asia. The biotechnology …
Merck withdraws Tredaptive
January 14, 2013Sales and Marketing EMA, Merck, tredaptive
Merck is mounting a global operation to withdraw its cholesterol-lowering drug Tredaptive from the market following safety concerns. The company …
Avastin shows brain cancer benefit
November 20, 2012Research and Development, Sales and Marketing Cancer, FDA, Merck, Roche, avastin, brain
In a Phase III trial, Roche’s Avastin has helped people with newly-diagnosed glioblastoma (GBM) live longer without their disease worsening. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
